Lantheus says CMS grants pass-through status for PYLARIFY TruVu
CMS granted transitional pass-through status for PYLARIFY TruVu (piflufolastat F 18).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) NASDAQ:LNTH, the leadin…